Korro Bio, Inc. (KRRO) Stock Analysis
A live, multi-source view of Korro Bio, Inc. (KRRO): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Sector: Healthcare · Industry: Biotechnology · United States · 57 employees · korrobio.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Korro Bio, Inc. (KRRO) had a market capitalization of $180.2M (forward -2.7) and a beta of 2.25; the shares traded in a 52-week range of $5.20 – $55.89 (-62.8% over the year).
- Market cap
- $180.2M
- Enterprise value
- $107.4M
- Forward P/E
- -2.7
- Price / book
- 1.74
- EPS (trailing)
- $-9.88
- EPS (forward)
- $-4.46
- Payout ratio
- 0.0%
- 52-week range
- $5.20 – $55.89
- 52-week change
- -62.8%
- Beta
- 2.25
- Average volume
- 176,220
- Shares outstanding
- 14.7M
- Short % of float
- 11.50%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Korro Bio, Inc. (KRRO) last closed at $12.93 (the last completed close before that scan).
Technicals at the scan: RSI 52 (neutral territory), price -0.5% versus its 20-day average, 20-day versus 50-day average spread +2.8%, MACD histogram -0.05.
Sentiment inputs: analyst consensus score 77/100.
Next scheduled company event: in 63 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of KRRO; corporate insiders filed 2 buys and 4 sells (2 distinct filers, latest disclosure 2026-08-28). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jean Francois Formela (0B/4S), Lynx1 Capital Management Lp (2B/0S). Who is trading what
RapidTradeView pick record
KRRO has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Korro Bio, Inc. (KRRO) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell KRRO.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.